SEC 13F Intelligence

Foresite Capital Management IV, LLC / KROS

Foresite Capital Management IV, LLC’s Keros Therapeutics Inc Position

Does Foresite Capital Management IV, LLC own Keros Therapeutics Inc (KROS)? Not currently — the last reported position was 1.38M shares worth $85M in Q1 2021; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$85M
Q1 2021
Shares
1.38M
% of Portfolio
+10.19%
Quarters Held
4
position exited

Position History KROS

Reported value by quarter
Q2 ’20: $54MQ2 ’20Q3 ’20: $54MQ3 ’20Q4 ’20: $100MQ4 ’20Q1 ’21: $85MQ1 ’21filingsflow.com
QuarterSharesValue% of Portfolio
Q1 20211.38M$85M+10.19%
Q4 20201.41M$100M+10.82%
Q3 20201.41M$54M+12.29%
Q2 20201.43M$54M+26.09%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Foresite Capital Management IV, LLC’s full portfolio or all institutional holders of KROS.